SWTX Earnings Prediction
The chart below shows how SWTX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, SWTX sees a -2.89% change in stock price 10 days leading up to the earnings, and a -2.33% change 10 days following the report. On the earnings day itself, the stock moves by +2.11%. This data can give you a slight idea of what to expect for the next quarter's release.
SWTX Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
49.30M
--
-17.46%
Gross Margin
93.22%
--
-2.78%
Operating Margin
-117.52%
--
56.28%
Net Margin
-108.58%
--
62.47%
EPS
-0.72
-43.31%
33.33%
No Data Available
SWTX Earnings Analysis
SpringWorks Therapeutics, Inc. Common Stock Corporation (SWTX.O) Earnings Conference Call
Positive
Third Quarter Revenue Growth: In the third quarter, we recorded $49.3 million of OGSIVEO net product revenue, representing a 23% growth over the second quarter.
Operating Expense Increase: Our total operating expense increased compared to the third quarter of 2023, driven by the commercial activities to support the U.S. launch of OGSIVEO and the anticipated U.S. launch of mirdametini.
Strong Financial Position: We have a strong balance sheet with $498 million in cash, cash equivalents and marketable securities as of the end of the third quarter.
Balance Sheet Sufficiency: We believe our balance sheet will be sufficient to fully fund our operations through profitability, an important milestone, which we expect to achieve in the first half of 2026.
2024 Accomplishments and Milestones: We are very pleased with our 2024 accomplishments to date and have several important milestones ahead of us.
Negative
Decline in Net Product Revenue: In the third quarter, we recorded $49.3 million of OGSIVEO net product revenue, which represents a decrease compared to previous quarters.
Operating Expenses Increase: Our total operating expenses increased compared to the third quarter of 2023, driven by the commercial activities to support the U.S. launch of OGSIVEO and the anticipated U.S. launch of mirdametinib.
Operating Expenses Impact: We have seen a significant increase in our operating expenses, which has impacted our overall profitability.
Funding Operations Challenges: Despite a strong balance sheet with $498 million in cash, we are facing challenges in funding our operations through profitability, which we expect to achieve in the first half of 2026.
Prescription Transition Delays: We have observed a two-week delay for many patients in getting their prescriptions as they transition from bottle to blister pack refills.
SWTX FAQs
How does SWTX typically perform around its earnings report dates?
Is SpringWorks Therapeutics, Inc. (SWTX) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
SWTX Earning Call Sentiment
SpringWorks Therapeutics, Inc. (SWTX) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
SWTX.O
-0.86%Positive
The earnings call highlights strong financial performance with significant growth in OGSIVEO revenue and a solid balance sheet. The product development and market strategy are promising, with plans for international expansion and new product launches. The Q&A revealed positive sentiment, with management indicating underestimated market size and steady patient growth, despite some supply chain challenges. While competitive pressures and regulatory issues pose risks, the overall outlook is optimistic. Given the market cap, a positive stock price movement of 2% to 8% is anticipated over the next two weeks.
